Emtricitabine, rilpivirine, and tenofovir alafenamide


Emtricitabine, rilpivirine, and tenofovir alafenamide

Drug updated on 11/27/2023

Dosage FormTablet (emtricitabine/ rilpivirine/tenofovir alafenamide; 200 mg/25 mg/ 25 mg)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY.